Compass Therapeutics (NASDAQ:CMPX) Receives Buy Rating from HC Wainwright

HC Wainwright reissued their buy rating on shares of Compass Therapeutics (NASDAQ:CMPX) in a research report released on Wednesday,Benzinga reports. The brokerage currently has a $10.00 price target on the stock.

Several other equities analysts have also commented on the company. D. Boral Capital restated a “buy” rating and set a $32.00 price target on shares of Compass Therapeutics in a research note on Wednesday. Leerink Partners lowered shares of Compass Therapeutics from an “outperform” rating to a “market perform” rating and reduced their price target for the company from $5.00 to $4.00 in a report on Friday, November 15th. Leerink Partnrs downgraded shares of Compass Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Friday, November 15th. Finally, LADENBURG THALM/SH SH raised shares of Compass Therapeutics from a “neutral” rating to a “buy” rating and set a $5.00 price objective on the stock in a report on Monday, September 16th. Two analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $11.80.

Compass Therapeutics Price Performance

Shares of CMPX opened at $1.86 on Wednesday. The firm has a market capitalization of $255.92 million, a price-to-earnings ratio of -5.03 and a beta of 0.92. Compass Therapeutics has a 1-year low of $0.77 and a 1-year high of $2.68. The company has a 50-day moving average of $1.57 and a 200 day moving average of $1.44.

Compass Therapeutics (NASDAQ:CMPX) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.08) earnings per share for the quarter, beating the consensus estimate of ($0.11) by $0.03. On average, equities analysts anticipate that Compass Therapeutics will post -0.35 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Compass Therapeutics

Institutional investors have recently bought and sold shares of the company. SG Americas Securities LLC lifted its holdings in shares of Compass Therapeutics by 16.6% during the 3rd quarter. SG Americas Securities LLC now owns 38,665 shares of the company’s stock valued at $71,000 after purchasing an additional 5,515 shares during the last quarter. Rhumbline Advisers increased its holdings in shares of Compass Therapeutics by 10.3% during the second quarter. Rhumbline Advisers now owns 131,789 shares of the company’s stock valued at $132,000 after acquiring an additional 12,315 shares in the last quarter. Rovin Capital UT ADV purchased a new position in shares of Compass Therapeutics in the 3rd quarter valued at approximately $25,000. Intech Investment Management LLC acquired a new stake in shares of Compass Therapeutics during the third quarter worth $30,000. Finally, Geode Capital Management LLC increased its holdings in shares of Compass Therapeutics by 0.8% in the third quarter. Geode Capital Management LLC now owns 2,309,778 shares of the company’s stock valued at $4,251,000 after purchasing an additional 19,095 shares during the period. 68.43% of the stock is currently owned by institutional investors and hedge funds.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.